671 Hormon Resistant Prostate Cancer Treated by Robotic High Intensive Ultrasound

Chaussy, C.; Thueroff, S.; Nanieva, Regina

doi:10.1016/j.juro.2010.02.1058

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifty-five men with PSA progression during definitive hormonal ablation and a local biopsy-proven tumour recurrence were treated with HIFU, with a mean follow-up of 21 months. Prostate-specific survival was 87.3% [36]. These data are impressive and encouraging because these are patients with a very poor prognosis and a short median survival.…”

Section: First Line Salvage Therapy After Deßnidve Treatmentmentioning

confidence: 80%

High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives

Palermo¹,

Pinto²,

Totaro³

et al. 2012

Scandinavian Journal of Urology

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is a minimally invasive therapy applied for prostate cancer that capitalizes on the coagulation necrosis that occurs at temperatures greater than 60°C. Owing to a lack of long-term follow-up data the procedure is still considered experimental treatment. As primary therapy, HIFU is indicated in patients aged ≥70 years with clinical organ-confined disease, although it has also been used, with encouraging results, as first line salvage therapy after definitive treatment, and in locally advanced (T3-4) and non-metastatic hormone-resistant prostate cancer. Morbidity associated with this treatment method appears to be low and includes urinary retention (1-9%), urethral stricture (4-14%), incontinence (1-15%), erectile dysfunction (13-53%) and rectourethral fistulae (0-3%). The risk of complications increases with repeated treatments. A few studies have recently been published on HIFU as focal therapy. HIFU technology can be enhanced using means such as ultrasound microbubble contrast agents for assessment of therapy efficacy, magnetic resonance imaging to guide the enhancement of heat rate, and localized drug and gene delivery.

show abstract

Section: First Line Salvage Therapy After Deßnidve Treatmentmentioning

confidence: 80%

High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives

Palermo¹,

Pinto²,

Totaro³

et al. 2012

Scandinavian Journal of Urology

View full text Add to dashboard Cite

show abstract

“…The median PSA velocity of this cohort was 0.19 ng/mL/y and the cancer-specific survival was 96.4%. Another study reported the outcomes of 55 men with PSA progression and local biopsy-proven tumor recurrence during definitive hormonal ablation therapy who received HIFU for hormonal resistant prostate cancer [58]. With a mean follow-up of 21 months, the prostate cancer-specific survival was 87.3%.…”

Section: Hifu Therapy In Locally Advanced Hormone-refractory and Admentioning

confidence: 99%

Transrectal High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Current Role

Chaussy¹,

Tilki²,

Thüroff³

2013

JCT

Self Cite

View full text Add to dashboard Cite

Over the past 25 years, the average life expectancy for men has increased by 4 years, and the age of prostate cancer detection has decreased an average of 10 years with diagnosis increasingly made at early-stage disease where curative therapy is possible. These changing trends in the age and extent of malignancy at diagnosis have revealed limitations in conventional curative therapies for prostate cancer, including a significant risk of aggressive cancer recurrence, and the risk of long-term genitourinary morbidity and its detrimental impact on patient quality of life (QOL). Greater awareness of the shortcomings in radical prostatectomy, external radiotherapy and brachytherapy have prompted the search for alternative curative therapies that offer comparable rates of cancer control and less treatment-related morbidity to better preserve QOL. High intensity focused ultrasound (HIFU) possesses characteristics that make it an attractive curative therapy option. HIFU is a non-invasive approach that uses precisely-delivered ultrasound energy to achieve tumor cell necrosis without radiation or surgical excision. In current urological oncology, HIFU is used clinically in the treatment of prostate cancer, and is under experimental investigation for therapeutic use in renal and breast malignancies. Clinical research on HIFU therapy for localized prostate cancer began in the 1990s, and there have now been approximately 30,000 prostate cancer patients treated with HIFU, predominantly with the Ablatherm (EDAP TMS, Lyon, France) device. Transurethral resection of the prostate (TURP) has been combined with HIFU since 2000 to reduce prostate size, facilitate tissue destruction, and to minimize side effects. Advances in imaging technologies are expected to further improve the already superior efficacy and morbidity outcomes, and ongoing investigation of HIFU as a focal therapy and in salvage and palliative indications are serving to expand the role of HIFU as a highly versatile non-invasive therapy for prostate cancer.

show abstract

“…The median PSA velocity of this cohort was 0.19 ng/mL/y and the cancer-specific survival was 96.4%. A series of 55 men with PSA progression during their definitive hormonal ablation with a local biopsy-proven tumor recurrence were reported [37]. With a mean follow-up of 21 months, the prostate-specific survival was 87.3%.…”

Section: High-intensity Focused Ultrasound In Locally Advanced (T3-4)mentioning

confidence: 99%

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Chaussy

Thüroff

2011

Curr Urol Rep

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is an emerging, noninvasive, local treatment of prostate cancer with 15 years of clinical experience, during which about 30,000 HIFU treatments have been performed worldwide. In this paper, we review relevant publications regarding the means by which new and old prostate cancer technologies are evaluated, the outcomes of HIFU by Ablatherm (EDAP TMS, Lyon, France), and the evolution currently underway regarding how prostate cancer is diagnosed and treated. We show the potential of HIFU to be used as local therapy for men with any stage of prostate cancer and how this additional therapeutic option can fit within the future armamentarium of a sequential multimodal therapy concept.

show abstract

671 Hormon Resistant Prostate Cancer Treated by Robotic High Intensive Ultrasound

Cited by 4 publications

References 0 publications

High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives

High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives

Transrectal High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Current Role

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Contact Info

Product

Resources

About